CD80 Antibody [12D9]

CD80 Antibody [12D9] | RF16046 | ProSci

Host: Mouse

Reactivity: Human

Homology: N/A

Immunogen: CD80 antibody was raised against the extracellular domain of human CD80.

Research Area: Immunology

Tested Application: E, WB, IHC-P, ICC, IF

Application: CD80 antibody can be used for detection of CD80 by Western blot at 0.5 - 1 μg/mL. Antibody can also be used for immunohistochemistry starting at 2 - 5 μg/mL. For immunofluorescence start at 5μg/mL.
Antibody validated: Western Blot in human samples; Immunohistochemistry in human samples; Immunocytochemistry in human samples; Immunofluorescence in human samples and Flow Cytometry in mouse samples. All other applications and species not yet tested.

Specificiy: N/A

Positive Control 1: Cat. No. 1340 - Human Stomach Carcinoma Tissue Lysate

Positive Control 2: Cat. No. 1315 - Human Tonsil Tissue

Positive Control 3: N/A

Positive Control 4: N/A

Positive Control 5: N/A

Positive Control 6: N/A

Molecular Weight: Predicted: 32 kDa
Observed: 50 kDa

Validation: N/A

Isoform: N/A

Purification: CD80 Antibody is supplied as protein A purified IgG1.

Clonality: Monoclonal

Clone: 12D9

Isotype: IgG1

Conjugate: Unconjugated

Physical State: Liquid

Buffer: CD80 Antibody is supplied in PBS containing 0.02% sodium azide and 50% glycerol.

Concentration: 1 mg/mL

Storage Condition: CD80 antibody can be stored at 4˚C for three months and -20˚C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.

Alternate Name: CD80 Antibody: CD80 molecule, B7, BB1, B7-1, B7.1, LAB7, CD28LG, CD28LG1

User Note: Optimal dilutions for each application to be determined by the researcher.

BACKGROUND: CD80 Antibody: CD80, also known as B7-1, is a type I membrane protein that is a member of the immunoglobulin superfamily. Like the related protein CD86, this protein is expressed by antigen-presenting cells, and is the ligand for two proteins at the cell surface of T cells, CD28 and the cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) . Binding of this protein with CD28 antigen is a costimulatory signal for activation of the T-cell and induces T-cell proliferation and cytokine production. CTLA-4 binding negatively regulates T-cell activation and diminishes the immune response (1) . Blocking the CTLA-4-CD80/CD86 interaction has been shown to enhance T-cell functions in acute lymphoblastomic leukemia (ALL) , suggesting that this pathway may be an attractive target for future cancer immunotherapy (2)